Nikhil Prasad Fact checked by:Thailand Medical News Team Dec 05, 2024 6 days, 17 hours, 39 minutes ago
Medical News: Glioblastoma multiforme, commonly known as GBM, is one of the deadliest brain tumors affecting thousands worldwide. Characterized by its aggressive nature, GBM is classified as a Grade 4 astrocytic glioma. This tumor predominantly affects adults aged 55 to 84 and has a grim prognosis, with only about 10% of patients surviving beyond two years post-diagnosis. The condition presents numerous challenges for treatment, and recent research focuses on the molecular mechanisms driving its progression, including the role of specific proteins like podoplanin (PDPN). This
Medical News report explores the groundbreaking study examining the connection between PDPN and the aggressive traits of GBM.
Understanding the Role of Podoplanin in Glioblastoma Progression
What is Podoplanin and Why It Matters
Podoplanin (PDPN) is a glycoprotein present on the surface of various cells, including some associated with cancer. It is involved in processes like tumor cell-induced platelet aggregation, lymphatic vessel formation, and tumor metastasis. Importantly, PDPN is often overexpressed in GBM, correlating with poor patient outcomes. Researchers from NYC Health and Hospitals Elmhurst and Icahn School of Medicine at Mount Sinai-USA have sought to understand the implications of PDPN's role in GBM to potentially establish it as a standalone prognostic marker.
The Study in Focus
In a recent comprehensive review, researchers analyzed preclinical and clinical evidence to unravel the significance of PDPN in GBM progression. PDPN-expressing cells possess remarkable malignant capabilities, transitioning from epithelial to mesenchymal states. This adaptability enables these cells to infiltrate surrounding tissues and drive metastasis.
PDPN is regulated by Prox1, a transcription factor, and contributes to pathological features like vascular anomalies and venous thromboembolism (VTE). GBM's association with abnormal platelet activation and aggregation is partly attributed to PDPN's interaction with platelet receptors, further enhancing its metastatic potential.
Key Findings from the Study
-PDPN and Immune Response Modulation: The study revealed that PDPN facilitates immune evasion by promoting the recruitment of immunosuppressive macrophages in the tumor microenvironment. These macrophages, predominantly M2-like, suppress anti-tumor immune responses, creating a favorable environment for GBM growth.
-Platelet Activation and VTE: PDPN triggers platelet activation via interactions with C-type lectin-like receptor-2 (CLEC-2). This mechanism not only aids tumor cell migration but also increases the risk of VTE in GBM patients, complicating treatment outcomes.
-Potential Prognostic Marker: High PDPN expression correlates with more aggressive GBM subtypes and reduced patient survival, emphasizing its potential as a prognostic marker.
Therapeutic Implic
ations
While PDPN's roles in GBM highlight its potential as a therapeutic target, challenges remain. Its interactions with CLEC-2 and involvement in platelet aggregation suggest that targeting these pathways could mitigate tumor progression and associated complications. However, clinical interventions require careful consideration to avoid disrupting physiological processes where PDPN plays a vital role.
Conclusions
The research underscores the multifaceted role of podoplanin in GBM, from modulating immune responses to driving metastasis. The findings suggest that PDPN could serve as both a biomarker for prognosis and a target for innovative therapies. Despite promising insights, further studies are necessary to validate PDPN's role and develop safe, effective interventions targeting this protein.
The study findings were published in the peer-reviewed journal: Cancers.
https://www.mdpi.com/2072-6694/16/23/4051
For the latest research on Glioblastoma, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/progenitor-cells-and-microglia-shape-glioblastoma-s-deadly-path
https://www.thailandmedical.news/news/hdac6-as-a-target-for-glioblastoma-multiforme-therapy
https://www.thailandmedical.news/news/unlocking-the-potential-of-liquid-biopsies-in-glioblastoma-diagnosis-and-treatment
https://www.thailandmedical.news/news/amino-acid-deprivation-as-a-new-hope-in-glioblastoma-treatment
https://www.thailandmedical.news/news/glioblastoma-may-weaken-key-immune-cells
https://www.thailandmedical.news/news/napabucasin-shows-promise-for-glioblastoma
https://www.thailandmedical.news/news/natural-compounds-show-promise-as-adjuvants-for-glioblastoma
https://www.thailandmedical.news/news/new-hope-for-glioblastoma-treatment-orladeyo-shows-promise-in-reducing-cerebral-edema
https://www.thailandmedical.news/news/a-new-promising-treatment-protocol-for-aggressive-type-of-malignant-brain-tumor
https://www.thailandmedical.news/news/university-of-mississippi-study-shows-that-juice-of-the-cornelian-cherry-can-help-with-glioblastoma
https://www.thailandmedical.news/news/hyperbaric-oxygen-aid-existing-treatments-against-brain-cancer
https://www.thailandmedical.news/news/metformin-shows-potential-as-an-angiogenic-supplemental-adjuvant-for-glioblastoma-treatment
https://www.thailandmedical.news/news/overcoming-drug-resistance-in-glioblastoma-the-promise-of-pi3k-beta-inhibitors
https://www.thailandmedical.news/news/herbs-and-phytochemicals-bioactive-compounds-from-kiwiberry-found-to-be-useful-in-treating-glioblastoma
https://www.thailandmedical.news/news/breaking-texas-md-anderson-study-finds-that-covid-19-accelerates-brain-tumor-progression-and-possibly-causes-new-onset-glioblastomas
https://www.thailandmedical.news/news/breaking-covid-19-news-study-finds-that-covid-19-hospitalization-linked-to-elevated-glioblastoma-risk-a-type-of-aggressive-brain-cancer
https://www.thailandmedical.news/news/brain-cancer-study-shows-lumefantrine-enhances-current-protocol-to-treat-glioblastoma-multiforme-gbm
https://www.thailandmedical.news/news/new-combo-therapy-for-glioblastoma
https://www.thailandmedical.news/news/new-liquid-biopsy-that-can-predict-brain-cancer-prognosis